HIGHLIGHTS
- who: Prognostic and collaborators from the University of Macau, China have published the research work: A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer, in the Journal: (JOURNAL)
- what: The authors identified genes affected by KRAS mutations and established a two-gene signature, which is a robust prognostic biomarker and a potential target for drug design. The study showed that low-KRGPS patients have low TMB scores, implying a lower likelihood of low-KRGPS patients benefiting from immune checkpoint inhibitors (ICIs).
- how: The sequence data . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.